603883.SHG Laobaixing Pharmacy
- Market cap
- CNY 11.4B
- P/E
- 24.7x
- P/B
- 1.73x
- ROE
- 12.3%
- Dividend yield
- 1.98%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 603883.SHG undervalued?
Graham number603883.SHG trades 37.7% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Laobaixing Pharmacy fundamental analysis
No fundamental analysis for Laobaixing Pharmacy yet.
Laobaixing Pharmacy stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Laobaixing Pharmacy
LBX Pharmacy Chain Joint Stock Company operates a chain of pharmacy stores in Mainland China. The company operates through three segments: Retail business, Wholesale business, and Other. It engages in commodity retail and wholesale business; and pharmaceutical manufacturing business and others, as well as sells drugs, and other health and beauty-related products through its marketing network. The company is also involved in wholesale and retail of pharmaceutical products; Ch…
Full company profileLaobaixing Pharmacy financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Laobaixing Pharmacy annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 6.09B | 7.50B | 9.47B | 11.7B | 14.0B | 15.7B | 20.2B | 22.4B | 22.4B | 22.2B | 22.2B |
| Gross Profit | 2.24B | 2.64B | 3.33B | 3.91B | 4.46B | 5.04B | 6.42B | 7.28B | 7.41B | 7.18B | 7.15B |
| Operating Income | 406M | 488M | 629M | 765M | 960M | 956M | 1.21B | 1.40B | 914M | 1.14B | 1.39B |
| EBITDA | 495M | 577M | 731M | 884M | 1.04B | 1.16B | 1.53B | 1.66B | 1.34B | 2.32B | 1.39B |
| Net Income | 297M | 371M | 435M | 509M | 621M | 669M | 785M | 929M | 519M | 382M | 824M |
| EPS | 0.61 | 0.76 | 0.84 | 0.97 | 1.17 | 1.26 | 1.36 | 1.22 | 0.68 | 0.50 | 1.09 |
| Balance Sheet | |||||||||||
| Total Assets | 4.91B | 6.70B | 8.48B | 9.92B | 11.3B | 17.0B | 21.4B | 21.2B | 22.2B | 19.8B | 19.1B |
| Total Liabilities | 2.96B | 3.60B | 5.12B | 6.05B | 6.48B | 12.2B | 14.3B | 13.9B | 15.0B | 12.8B | 12.0B |
| Shareholders' Equity | 1.85B | 2.93B | 3.05B | 3.49B | 4.29B | 4.36B | 6.53B | 6.70B | 6.58B | 6.54B | 6.68B |
| Cash & Short-term Investments | 835M | 1.35B | 1.12B | 1.40B | 1.40B | 1.41B | 2.41B | 1.98B | 2.38B | 2.36B | 2.09B |
| Total Debt | 1.27B | 1.07B | 1.71B | 1.85B | 1.30B | 6.03B | 5.46B | 5.03B | 10.3B | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 313M | 492M | 913M | 1.03B | 1.45B | 2.30B | 2.31B | 2.73B | 2.03B | 3.14B | - |
| Capital Expenditure | 206M | 305M | 873M | 426M | 394M | 479M | 308M | 621M | 508M | 253M | 158M |
| Free Cash Flow | 108M | 187M | 39.6M | 606M | 1.05B | 1.82B | 2.01B | 2.11B | 1.52B | 2.89B | 2.78B |
| Ratios | |||||||||||
| ROE | 16.0% | 12.7% | 14.3% | 14.6% | 14.5% | 15.4% | 12.0% | 13.9% | 7.9% | 5.8% | 12.3% |
| ROA | 6.0% | 5.5% | 5.1% | 5.1% | 5.5% | 3.9% | 3.7% | 4.4% | 2.3% | 1.9% | 4.3% |
| Net Profit Margin | 4.9% | 4.9% | 4.6% | 4.4% | 4.4% | 4.3% | 3.9% | 4.1% | 2.3% | 1.7% | 3.7% |
| Debt to Equity | 0.69x | 0.37x | 0.56x | 0.53x | 0.30x | 1.38x | 0.84x | 0.75x | 1.57x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Laobaixing Pharmacy dividends
- Dividend yield
- 1.98%
- Forward dividend
- 0.71 CNY
- Payout ratio
- 58.8%
- Ex-dividend date
- Sep 10, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 225M | 0.30 | 58.8% |
| 2024 | CNY 637M | 0.83 | 122.8% |
| 2023 | CNY 375M | 0.49 | 40.3% |
| 2022 | CNY 224M | 0.39 | 28.5% |
| 2021 | CNY 143M | 0.27 | 21.4% |
| 2020 | CNY 123M | 0.23 | 19.7% |
| 2019 | CNY 143M | 0.27 | 28.2% |
| 2018 | CNY 338M | 0.65 | 77.7% |
| 2017 | CNY 129M | 0.26 | 34.7% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.3:1 on Jun 27, 2024.
Who owns Laobaixing Pharmacy
- Insiders 49.51%
- Institutions 3.34%
- Public & others 47.14%
- Shares outstanding 767M
- Free float 379M
Laobaixing Pharmacy company profile
- Company name
- Laobaixing Pharmacy
- Ticker
- 603883.SHG
- ISIN
- CNE1000023Q8
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Consumer Staples Distribution & Retail
- Employees
- 36,892
- Fiscal year end
- December
- Address
- No. 808, Qingzhuhu Road, Changsha, China, 410152
- Phone
- 86 731 8403 5189
- Website
- lbxdrugs.com
About Laobaixing Pharmacy
LBX Pharmacy Chain Joint Stock Company operates a chain of pharmacy stores in Mainland China. The company operates through three segments: Retail business, Wholesale business, and Other. It engages in commodity retail and wholesale business; and pharmaceutical manufacturing business and others, as well as sells drugs, and other health and beauty-related products through its marketing network. The company is also involved in wholesale and retail of pharmaceutical products; Chinese medicine research and development; e-commerce; food and department store retail; commodity wholesale; and retail of maternal and infant products. In addition, it provides business, information technology consulting, pharmaceutical internet information, information consulting, clinic, and medical services. The company was formerly known as Laobaixing Pharmacy Chain Joint Stock Company. LBX Pharmacy Chain Joint Stock Company was founded in 2001 and is headquartered in Changsha, China.
Laobaixing Pharmacy management
10- Mr. Zilong XieChairman & President · born 1966
- Mr. Lishan ChenVP & CFO · born 1979
- Ms. Shini FengVP & Company Secretary · born 1985
- Mr. Shiyong SuVice President · born 1975
- Mr. Xin WanVice President · born 1984
- Mr. Wenshuai ZhangVice President · born 1986
- Ms. Xian DangVice President · born 1981
- Ms. Huan LinVice President · born 1982
- Shi LeiHead of Accounting
- Yunxin HuangInvestor Relations Manager